CYD-TDV vaccine a new era of success in coping with Dengue infection

Dengue infection is a classic endemic viral disease affecting 100 million individuals annually, especially in the East Asian peninsula, which hosts 70% of all the dengue outbreaks. [1]

CYD-TDV a tetravalent dengue vaccine was introduced to cope with dengue infectivity and to reduce the severity of dengue infection in patients especially in third world developing countries, for this reason a three phase multicenter trial was hosted in five Asian countries in the year 2011, the trial aimed to show the efficacy of the CYD-TDV in reducing the severity of dengue infection in children aged between 2-14 and providing protection from the virus in a period of 25-month following the administration of three injections at months 0, 6, and 12. [2][3]

A computerized system selected 6710 children of the 10 275 children enrolled in the trial to receive three live attenuated CYD-TDV injections at months 0, 6, and 12, whereas the remaining 3350 children received a placebo for case control. The primary interpretation of the trial showed that CYD-TDV successfully reduced the risk of dengue infection in children when compared to the control group (117 cases compared to 133 cases), as well as it reduced the number of children admitted into hospitals and prevented complications such as dengue haemorrhagic fever in more than 80% of patients, furthermore, vaccination Efficacy was higher in children with preexisting dengue antibodies than in those who were seronegative. [4][5][6][7]

In summary, after 2 years of intense case monitoring, results obtained proven the beneficial effects of the three phase CYD-TDV vaccination on the severity and symptoms of Dengue infection in the trialed children, which encourages and support CYD-TDV vaccination, especially in the dengue-endemic countries of East Asia.

 

 

 

 

References

1. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective effi cacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380: 1559–67.
2. Bhatia R, Dash A, Sunyoto T. Changing epidemiology of dengue in South-East Asia. WHO-SEAJPH 2013; 2: 23–27.
3. Dengue: guidelines for diagnosis, treatment, prevention and control. New edition. 2009. http://www.who.int/tdr/publications/ documents/dengue-diagnosis.pdf (accessed June 7, 2014).
4. Dayan GH, Thakur M, Boaz M, Johnson C. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine 2013; 31: 5047–54.
5. Leo YS, Wilder-Smith A, Archuleta S, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 2012; 8: 1259–71.
6. Tran NH, Luong CQ, Vu TQH, et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin 2012; 3: 1–7.
7. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd edn. 1997. http://www.who.int/csr/ resources/publications/dengue/Denguepublication/en/ (accessed June 7, 2014).

Verified by: Dr.Diab (January 7, 2017)

Citation: Dr.Diab. (January 7, 2017). CYD-TDV vaccine a new era of success in coping with Dengue infection. Medcoi Journal of Medicine, 6(2). urn:medcoi:article16564.